IMC-TR1 / Eli Lilly - LARVOL DELTA

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial. (PubMed, Trials) - "We hypothesize that patients with low-to-medium-risk hypertension will benefit from BSJY. If successful, this study will provide evidence-based recommendations for clinicians."

Biomarker • Clinical • Journal • Cardiovascular • Hypertension • Hypotension • Inflammation

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. (PubMed) - Cancer Chemother Pharmacol - P1; "The MTD for LY3022859 was not determined. Dose escalation beyond 25 mg was considered unsafe due to worsening symptoms (uncontrolled cytokine release) despite prophylaxis (corticosteroids and antihistamines)."

Journal • Biosimilar • Oncology